MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS (ESAS): A REAL-LIFE EXPERIENCE

被引：0
|
作者：
Cerchione, C. [1 ]
Vitagliano, O. [1 ]
Pareto, A. E. [1 ]
Di Perna, M. [1 ]
Cerciello, G. [1 ]
Soriente, I. [2 ]
Alfinito, F. [1 ]
Pane, F. [1 ]
机构：
[1] Hematol Ematol & Trapianto Federico II, Naples, Italy
[2] Osped Umberto I, Hematol, Nocera Inferiore, SA, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB2114
引用
收藏
页码：840 / 840
页数：1
相关论文
共 50 条
  • [31] Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
    Kosmider, Olivier
    Passet, Marie
    Santini, Valeria
    Platzbecker, Uwe
    Andrieu, Valerie
    Zini, Gina
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Masala, Erico
    Balleari, Enrico
    Bulycheva, Ekaterina
    Dreyfus, Francois
    Fenaux, Pierre
    Fontenay, Michaela
    Park, Sophie
    HAEMATOLOGICA, 2016, 101 (07) : 280 - 283
  • [32] Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
    Moyo, Victor
    Lefebvre, Patrick
    Duh, Mei Sheng
    Yektashenas, Behin
    Mundle, Suneel
    ANNALS OF HEMATOLOGY, 2008, 87 (07) : 527 - 536
  • [33] Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
    Smith, Sheila Weiss
    Sato, Masayo
    Gore, Steven D.
    Baer, Maria R.
    Ke, Xuehua
    McNally, Diane
    Davidoff, Amy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (01): : 15 - 20
  • [34] Drug utilization and cost considerations of erythropoiesis-stimulating agents in patients with myelodysplastic syndromes
    Lalibert, Francois
    McKenzie, Scott R.
    Bookhart, Brahim K.
    Duh, Mei S.
    Lefebvre, Patrick
    BLOOD, 2007, 110 (11) : 225B - 225B
  • [35] Efficacy and safety of erythropoiesis stimulating agents (ESAs) in Myelofibrosis-A single-centre experience
    Mohamed, Amany Ihab
    Leong, Jonathan
    Elsayed, Yasmin
    Teh, Chun Huat
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 92 - 92
  • [36] Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma
    Katodritou, Eirini
    Dimopoulos, Meletios A.
    Zervas, Konstantinos
    Terpos, Evangelos
    CANCER TREATMENT REVIEWS, 2009, 35 (08) : 738 - 743
  • [37] Erythropoiesis stimulating agents (ESAs) for congestive heart failure: The red and the black
    Roberto Robles, Nicolas
    Francisco Macias, Juan
    Herrera, Julio
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (02) : 193 - 196
  • [38] Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS)
    Veys, N.
    Van Biesen, W.
    Lameire, N.
    ACTA CLINICA BELGICA, 2007, 62 (06) : 396 - 407
  • [39] Patterns of care in patients with chemotherapy receiving erythropoiesis stimulating agents (ESAs)
    Naeim, Arash
    Friedman, Lyssa
    Elkin, Eric
    Adams, Sara
    Viswanathan, Hema
    Kallich, Joel
    Glaspy, John
    BLOOD, 2007, 110 (11) : 294A - 294A
  • [40] Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
    Drüeke T.B.
    Renal Replacement Therapy, 4 (1)
12345